A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Pembrolizumab versus Docetaxel with or without Ramucirumab in Patients with Previously Treated Non-Small Cell Lung Cancer
NCT #
NCT05062980
Condition(s)
Lung Cancer (NSCLC)
Molecular Target(s)
Not Required
Drug Classification(s)
Gene Therapy
Agents(s)
III
Phase(s)
I/II
Mechanism of Action
DNA-lipid complex containing the TUSC2 gene
Purpose
- How much of the study agent in combination with pembrolizumab can be given with an acceptable level of side effects
- The effects of the study agent and pembrolizumab (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- The effects of the study agent and pembrolizumab when compared to cancer treatments that are approved for your cancer
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.